Please wait...
176
34
Offers Claimed: 117
Downloaded Today: 44
Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:
Yes
99% of Medicare Part D and Medicare Advantage plans cover this drug.It depends. Which coverage stage are you in? Click on a tab below…
$42 – $1040
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your creon prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Note: This document contains side effect information about pancrelipase. Some of the dosage forms listed on this page may not apply to the brand name Creon.
In SummaryMore frequent side effects include: headache. See below for a comprehensive list of adverse effects.
For the ConsumerApplies to pancrelipase: oral capsule delayed release, oral tablet
Along with its needed effects, pancrelipase (the active ingredient contained in Creon) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking pancrelipase:
Rare
With high doses
With very high doses
With powder dosage form or powder from opened capsules
- if breathed inWith tablets
- if held in the mouthIncidence not known
Some side effects of pancrelipase may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
Less common
Incidence not known
For Healthcare Professionals
Applies to pancrelipase: oral capsule, oral capsule extended release, oral delayed release capsule, oral powder for reconstitution, oral tablet, oral tablet extended release
GeneralThe most commonly reported side effects included gastrointestinal complaints, abdominal pain, and headaches.
GastrointestinalBowel stricture formation occasionally occurred in children with cystic fibrosis who received high doses.
Moderate duodenitis and gastritis occurred in a patient with exocrine pancreatic insufficiency due to cystic fibrosis 16 days after completing treatment with 4000 lipase units/gram fat ingested per day for 5 to 6 days, followed by placebo for an additional 5 to 6 days.
Very common (10% or more): Gastrointestinal complaints (up to 32%), abdominal pain (up to 18%)
Common (1% to 10%): Abdominal distention, abdominal pain upper, abnormal feces, anal pruritus, ascites, constipation, diarrhea, dyspepsia, early satiety, flatulence, frequent bowel movements, nausea, vomiting
Uncommon (0.1% to 1%): Abdominal discomfort, bowel stricture formation
Frequency not reported: Duodenitis, fibrosing colonopathy, gastritis, steatorrhea, strictures of the ileocecum
Postmarketing reports: Distal intestinal obstruction syndrome (DIOS)
Nervous systemVery common (10% or more): Headache (up to 15%)
Common (1% to 10%): Dizziness
Postmarketing reports: Dull headache
A dull headache was reported by a patient receiving treatment with ursodeoxycholic acid concomitantly. The event resolved without sequelae after discontinuation of this drug.
MetabolicCommon (1% to 10%): Decreased appetite, hyperglycemia, hypoglycemia, weight decreased
Frequency not reported: Hyperuricemia
DermatologicCommon (1% to 10%): Rash, skin reactions
Frequency not reported: Pruritus/itching, urticaria/hives
Postmarketing reports: Blotchy/red facial rash
HepaticCommon (1% to 10%): Biliary tract stones, hydrocholecystis
Postmarketing reports: Asymptomatic liver enzyme elevations
RespiratoryCommon (1% to 10%): Cough, nasopharyngitis
Postmarketing reports: Asthma
CardiovascularCommon (1% to 10%): Contusion, peripheral edema
HematologicCommon (1% to 10%): Anemia
Frequency not reported: Transient neutropenia with/without clinical sequelae
RenalCommon (1% to 10%): Renal cyst
PsychiatricCommon (1% to 10%): Irritability
ImmunologicCommon (1% to 10%): Viral infection
HypersensitivityA patient with a known history of allergy to another pancrelipase (the active ingredient contained in Creon) product developed a mild allergic reaction, including red, blotchy facial rash and itching. The event resolved without sequelae after discontinuation of this drug.
Frequency not reported: Anaphylactic reactions, hypersensitivity
Postmarketing reports: Anaphylaxis, mild allergic reactions, severe allergic reactions
OtherFrequency not reported: Fatigue
MusculoskeletalPostmarketing reports: Muscle spasm, myalgia
OncologicPostmarketing reports: Recurrence of preexisting carcinoma
OcularPostmarketing reports: Blurred vision
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/3/2022.
Source: Drugs.com Creon (www.drugs.com/creon.html).
August 4, 2022
August 4, 2022
August 4, 2022
July 26, 2022
July 26, 2022
July 22, 2022